Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Oct 31;9(2):e0020521.
doi: 10.1128/Spectrum.00205-21. Epub 2021 Oct 13.

Comparative Performance of a New SARS-CoV-2 Rapid Detection System

Affiliations
Comparative Study

Comparative Performance of a New SARS-CoV-2 Rapid Detection System

Gianni Gori Savellini et al. Microbiol Spectr. .

Abstract

The extraordinary global demand for reagents and diagnostic instruments needed for timely detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly affected their availability. In order to meet diagnostic needs, it has been necessary to develop new diagnostic procedures. To date, molecular diagnostic tools have represented the gold standard for diagnosis of SARS-CoV-2 infection, and thus an alternative and real-time PCR system was required. To this aim, a molecular rapid test which works with direct real-time RT-PCR may be a relevant aid. In the present work, the accuracy, sensitivity, and specificity of the bKIT Virus Finder COVID-19 rapid molecular test by Hyris Ltd. was evaluated. Moreover, the influence of a different swab storage medium composition was examined relative to that of a routinely used comparator assay. The Hyris Ltd. assay showed an overall agreement of 100% with the comparator based on a panel consisting of 74 retrospective positive nasopharyngeal swabs (NPSs), collected either in universal transport medium (UTM) or using ESwab. No false-positive result was achieved on samples that previously tested negative. Cross-reactivity screening on microorganisms that commonly colonize the human upper respiratory tract was not detected, excluding the risk of false-positive results. Simultaneously, drugs frequently administered to cure respiratory diseases did not interfere with the analytical performance of the assay. Our results showed that the Hyris Ltd. bKIT Virus Finder COVID-19 is a reliable assay for rapid qualitative detection of SARS-CoV-2, providing the advantage of less complex and unambiguous interpretation of results. Indeed, skilled technicians are not required, and thus the Hyris system is suitable as a rapid and easy system for SARS-CoV-2 diagnosis. IMPORTANCE In order to overcome the increased demand for diagnostic tools for the timely detection of SARS-CoV-2 infection, we tested the bKIT Virus Finder COVID-19 molecular rapid test by Hyris Ltd. The new system was confirmed as a reliable assay for rapid SARS-CoV-2 detection, since sensitivity and specificity parameters were fully satisfied. Moreover, the bKIT Virus Finder COVID-19 provides the advantage of easy results interpretation, since skilled technicians are not required, and thus the Hyris system is a valuable SARS-CoV-2 rapid diagnosis system.

Keywords: SARS-CoV-2; diagnostic platform; molecular diagnosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Scheme of the Hyris bCUBE cartridge. Clinical samples and positive and negative controls should be loaded on the cartridge two times, as shown by the cartridge layout (A) for testing with reaction mix 1 (blue) and reaction mix 2 (yellow) (B). Evaluation of results is automatically performed, matching all the included controls in order to avoid the generation of false-positive or false-negative data.

Similar articles

Cited by

References

    1. Rong XM, Yang L, Chu HD, Fan M. 2020. Effect of delay in diagnosis on transmission of COVID-19. Math Biosci Eng 17:2725–2740. doi:10.3934/mbe.2020149. - DOI - PubMed
    1. Lilleri D, Zavaglio F, Gabanti E, Gerna G, Arbustini E. 2020. Analysis of the SARS-CoV-2 epidemic in Italy: the role of local and interventional factors in the control of the epidemic. PLoS One 15:e0242305. doi:10.1371/journal.pone.0242305. - DOI - PMC - PubMed
    1. Sethuraman N, Jeremiah SS, Ryo A. 2020. Interpreting diagnostic tests for SARS-CoV-2. JAMA 323:2249–2251. doi:10.1001/jama.2020.8259. - DOI - PubMed
    1. Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B. 2020. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). Clin Chim Acta 510:35–46. doi:10.1016/j.cca.2020.06.045. - DOI - PMC - PubMed
    1. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Domen J, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, McInnes MD, Spijker R, Van den Bruel A, Cochrane COVID-19 Diagnostic Test Accuracy Group . 2021. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 3:CD013705. doi:10.1002/14651858.CD013705.pub2. - DOI - PMC - PubMed

Publication types

MeSH terms